



PHARMACY POLICY STATEMENT

DRUG NAME	Adakveo (crizanlizumab-tmca)
BILLING CODE	J0791
BENEFIT TYPE	Carved out to FFS (fee-for-service) benefit
SITE OF SERVICE ALLOWED	N/A
COVERAGE REQUIREMENTS	Please see Indiana Fee-For-Service website

Adakveo (crizanlizumab-tmca) is a product that is carved out from managed care benefits and is included in the Indiana Medicaid Fee-For-Service (FFS) program. Requests for coverage of this product must be submitted directly to OptumRx for review.

Statement regarding the carved-out status created.

Effective date: 05/25/2020

Revised date: 05/19/2020